Structure Therapeutics (GPCR) announced the first patients have been dosed in the randomized, double-blind, placebo-controlled Phase 2b ACCESS ...

Structure Therapeutics, Inc. Sponsored ADR ( (GPCR) ) has released its Q3 earnings. Here is a breakdown of the information Structure ...

Structure Therapeutics Inc. (NASDAQ:GPCR) was able to report positive results from its phase 2a study using its GLP-1R agonist GSBR-1290 for the treatment of patients with obesity in June 2024.

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Nxera will hold an exclusive licence for the antibody assets globally, granting full rights for their development and ...

The two-year-old South San Francisco-based biotech – which focuses on the development of small-molecule drugs targeting G ...

Structure Therapeutics (NASDAQ:GPCR) is a biotechnology company developing oral therapies targeting G-protein-coupled ...

Shares of “SEPN” will begin trading Friday on the Nasdaq stock exchange. GPCRs, or G protein-coupled receptors, are something of a cellular jack of all trades, involved in a range of ...

PTH1R is a G protein coupled-receptor (GPCR), part of a family of receptors that regulate a wide range of physiological processes. The role of these receptors in both health and disease is known ...

Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor appetite for its G protein-coupled receptors (GPCRs). The South San ...

Nxera Pharma & Antiverse collaborate to design novel GPCR-targeted antibody therapeutics using generative AI: Tokyo, Japan Wednesday, November 6, 2024, 13:00 Hrs [IST] Nxera Pharm ...